Alpenglow News & Updates

Alpenglow Biosciences Introduces LUMI: A Breakthrough Imaging Interface

Alpenglow Biosciences and Incyte Corporation to Present 3D Imaging Research at SID 2025
Alpenglow Biosciences and Incyte Corporation will present groundbreaking 3D imaging research at SID 2025, showcasing how 3D imaging reveals neuroimmune dynamics in atopic dermatitis treated with ruxolitinib cream. Using Alpenglow’s Aurora 3Di light-sheet microscopy, the study provides unprecedented insights into nerve volume, immune cell distribution, and epidermal remodeling.

We Announce Our ePoster Presentation at SID

Alpenglow Biosciences CEO Nick Reder shared his insights on NIH funding cuts in the Washington Post.

Alpenglow Biosciences is Recognized as a rising Leader in 3D Spatial Biology.

Alpenglow Biosciences CEO Nick Reder, MD, MPH, to Present at the Dermatology Summit 2025

Poster presentation at Multi-Omics Brisbane 2024

Dinner Lecture at SITC24 by Prof. Pei-Ling Chen: “Spatially resolved immunologic hallmarks of response to immune checkpoint blockade therapies in metastatic melanoma in 2D and 3D.”

Final Agenda Announced for the 3D Spatial Summit 2024: Join Leading Academics and Industry Experts on October 17th in Cambridge, MA

Alpenglow Biosciences Secures $24M+ in ARPA-H and NIH Contracts to Revolutionize Cancer and Prostate Diagnostics

Win a $50,000 3D I/O Pro™ research grant from Alpenglow
Alpenglow unveils a $50,000 research grant program for novel applications of its brand new 3D I/O Pro assay. Unlock insights into the tumor microenvironment with whole tissue 3D imaging and analysis.

Alpenglow Biosciences Announces Immediate Availability of 3D Derm Score Assay for Research into complex diseases of the skin
We have developed the 3D Derm Score Assay to reveal the complexities of the skin microenvironment and determine the relationship between critical structures in the epidermis and dermis.

Alpenglow Biosciences, Inc. Sponsors Dinner Lecture titled “Decoding Immune Exclusion and Tumor Evasion in the TME”, featuring Dr. Laura Dillon, PhD of Incendia Therapeutics
Alpenglow Biosciences sponsors dinner lecture titles “Decoding Immune Exclusion and Tumor Evasion in the TME” during the 2023 annual SITC meeting

Announcing the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology on September 21, 2023 in Cambridge, Massachusetts
Alpenglow Biosciences presents the 3D Spatial Summit, an inaugural event for the field of 3D Spatial Biology to take place on September 21, 2023 in Cambridge, Massachusetts

Alpenglow awarded $1.6M grant to develop AI-enabled smart microscopy and 3D cancer database
Alpenglow Biosciences awarded $1.6M grant to develop AI-enabled smart microscopy and 3D database of cancer biopsies

Accelerating Drug Development with AI-Enabled 3D Spatial Biology
Accelerating Drug Development with AI-Enabled 3D Spatial Biology, an interview with CEO Nicholas Reder and David Alvaro of Pharma’s Almanac

Alpenglow Biosciences and Mayo Clinic enter collaboration agreement to advance pathology and drug development
Alpenglow collaborates with Mayo Clinic to accelerate drug development and improve clinical diagnostics.
Alpenglow accelerates progress with key commercial hires including Spatial Biology industry veterans
Alpenglow accelerates progress with key commercial hires including Spatial Biology industry veterans.
